The Canadian government has announced the establishment of the Canadian Drug Agency (CDA) to address the challenges faced by Canadians in accessing affordable prescription medications. High drug costs, inconsistent standards for prescribing practices, and limited access to health data have left many Canadians vulnerable. The CDA, built upon the existing Canadian Agency for Drugs and Technologies in Health (CADTH), will provide dedicated leadership and coordination to improve the sustainability of Canada's drug system.
With an investment of $89.5 million over five years, the CDA will expand CADTH's mandate and functions to include initiatives such as appropriate prescribing practices, enhanced data collection and access to drug information, and reduction of inefficiencies in the drug system. Through these efforts, the CDA aims to improve health outcomes for Canadians and ensure that they can access the medications they need now and in the future.
The creation of the CDA builds upon the progress made by the Canadian government towards a national pharmacare program. The agency's establishment follows the Improving Affordable Access to Prescription Drugs initiative, which has already saved Prince Edward Island residents over $1.7 million in out-of-pocket costs on more than 195,000 prescriptions.
Moreover, the government has also invested up to $1.5 billion over three years to support the National Strategy for Drugs for Rare Diseases, aiming to increase access and affordability of effective drugs for rare diseases across Canada, including children. By incorporating CADTH's expertise in the pharmaceutical sector and collaborating with provinces and territories, the CDA seeks to create a sustainable and efficient drug system that benefits all Canadians.